Instead for gliomas, as expanded below, there may be opportunities to expand the treatment repertoire using PARP inhibitors in combination with radiotherapy, chemotherapy and immunotherapy, and in selected subgroups such as IDH-mutant glioma (Figure 2). This evidence concerns the gene PARP1 and central nervous system cancer.